BDBM562790 (2S,5R,6S)-4-((R)-1-(1H-Tetrazol-5-yl)butyl)-5,6-bis(4-chlorophenyl)-2-(4-iodobenzyl)morpholin-3-one and (2R,5S,6R)-4-((S)-1-(1H-tetrazol-5-yl)butyl)-5,6-bis(4-chlorophenyl)-2-(4-iodobenzyl)morpholin-3-one::US11407721, Example 36

SMILES CCC[C@H](N1[C@H]([C@H](O[C@H](Cc2ccc(I)cc2)C1=O)c1ccc(Cl)cc1)c1ccc(Cl)cc1)c1nnn[nH]1

InChI Key InChIKey=HCAYISRYXICNRK-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 562790   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562790(US11407721, Example 36 | (2S,5R,6S)-4-((R)-1-(1H-T...)
Affinity DataIC50: 712nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562790(US11407721, Example 36 | (2S,5R,6S)-4-((R)-1-(1H-T...)
Affinity DataIC50: 514nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent